Cwm LLC Boosts Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Cwm LLC raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 46.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,955 shares of the biotechnology company’s stock after purchasing an additional 27,894 shares during the period. Cwm LLC’s holdings in BioMarin Pharmaceutical were worth $4,835,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 212.7% in the first quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock worth $112,607,000 after buying an additional 1,083,512 shares in the last quarter. Covea Finance lifted its holdings in shares of BioMarin Pharmaceutical by 27.3% in the second quarter. Covea Finance now owns 135,300 shares of the biotechnology company’s stock worth $7,437,000 after buying an additional 29,000 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of BioMarin Pharmaceutical by 154.0% in the first quarter. GAMMA Investing LLC now owns 3,129 shares of the biotechnology company’s stock worth $221,000 after buying an additional 1,897 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in shares of BioMarin Pharmaceutical by 12.3% in the first quarter. Robeco Institutional Asset Management B.V. now owns 97,261 shares of the biotechnology company’s stock worth $6,875,000 after buying an additional 10,687 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of BioMarin Pharmaceutical by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,064,924 shares of the biotechnology company’s stock worth $75,279,000 after buying an additional 9,837 shares in the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock opened at $52.95 on Friday. BioMarin Pharmaceutical Inc. has a fifty-two week low of $51.56 and a fifty-two week high of $73.51. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.60 and a current ratio of 5.56. The firm’s fifty day moving average price is $55.74 and its 200-day moving average price is $57.67. The stock has a market cap of $10.17 billion, a P/E ratio of 15.71, a price-to-earnings-growth ratio of 0.67 and a beta of 0.33.

Analyst Upgrades and Downgrades

BMRN has been the topic of a number of recent analyst reports. HC Wainwright initiated coverage on shares of BioMarin Pharmaceutical in a report on Monday, September 8th. They issued a “neutral” rating and a $60.00 price target on the stock. Raymond James Financial began coverage on shares of BioMarin Pharmaceutical in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $85.00 price target on the stock. Wolfe Research set a $95.00 target price on shares of BioMarin Pharmaceutical and gave the company an “outperform” rating in a research note on Tuesday, July 15th. Morgan Stanley lowered their target price on shares of BioMarin Pharmaceutical from $97.00 to $96.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 22nd. Finally, Wall Street Zen lowered shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 11th. Thirteen investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $93.26.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.